Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2018

Kobayashi Yoshihisa, Fujino Toshio, Nishino Masaya, Koga Takamasa, Chiba Masato, Sesumi Yuichi, Ohara Shuta, Shimoji Masaki, Tomizawa Kenji, Takemoto Toshiki, Mitsudomi Tetsuya

Abstract excerpt

INTRODUCTION: Dacomitinib was superior to gefitinib in terms of progression-free survival in patients with EGFR-mutant lung cancer in a recent ARCHER 1050 trial. However, despite a marked initial response, lung cancers eventually acquire resistance to these inhibitors. This study aimed to elucidate the mechanisms of acquired resistance to dacomitinib in vitro. METHODS: Dacomitinib-resistant clones were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Quinazolinones

Share to Transfection

Source

Identifiers

PMID: 29410323
DOI: 10.1016/j.jtho.2018.01.009

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.PMID 29410323Read ↗

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.Semantic proximity Read ↗

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.Semantic proximity Read ↗

Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.Semantic proximity Read ↗

Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.Semantic proximity Read ↗

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.Semantic proximity Read ↗

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment StrategySemantic proximity Read ↗

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib TreatmentSemantic proximity Read ↗

Potential Utility of a 4th Generation EGFR-TKI and Exploration of Resistance Mechanisms – an In Vitro StudySemantic proximity Read ↗

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.Semantic proximity Read ↗

Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.Semantic proximity Read ↗

Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro StudySemantic proximity Read ↗

Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.